Back to LA LINDEN ADVISORS LP
BBIO
Showing 0 of 2 quarters
Position history for LALINDEN ADVISORS LP's holdings in BRIDGEBIO PHARMA INC
No. Linden Advisors exited its BBIO (Bridgebio Pharma) position in Q2 2020. Its Q1 2020 13F listed 47,255 shares worth $1.4M. Linden Advisors first reported BBIO in Q1 2020 and held it in 1 quarterly 13F filing.
Current Value
—
Current Shares
—
Total Value Change
$0
Total Shares Change
0
No position history available for this security.